Freenome, Inc. (FRNM)
NASDAQ: FRNM · Real-Time Price · USD
15.95
+0.70 (4.59%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Company Description

Freenome, Inc. operates as a biotechnology company in the United States.

The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer.

It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers.

The company was founded in 2014 and is headquartered in Brisbane, California.

Freenome, Inc.
CountryUnited States
Founded2014
IndustryDiagnostics & Research
SectorHealthcare
Employees381
CEOAaron Elliott

Contact Details

Address:
3300 Marina Boulevard
Brisbane, California 94005
United States
Phone(650) 446-6630
Websitefreenome.com

Stock Details

Ticker SymbolFRNM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0002017526
CUSIP Number35661P100
ISIN NumberUS35661P1003

Key Executives

NamePosition
Aaron Elliott Ph.D.Chief Executive Officer and Director
Riley EnnisCo-Founder and Chief Product Officer
Linh H. LeChief Financial Officer
Cheng-Ho Lin M.D., MHS, Ph.D.Chief Scientific Officer
Thomas F. Fitzpatrick J.D.Chief Legal Officer
Julie Tran M.B.A., MSHRChief People Officer
Sally Howard J.D.Senior Vice President of Regulatory and Quality
Robert GuigleyChief Commercial Officer